Skip to main content

Amaya offices are shown in this undated photo.

Ryan Remiorz/THE CANADIAN PRESS

About a dozen brokers at the Montreal-area branch of Manulife Securities Inc. are under investigation by Quebec's securities regulator as part of its probe into widespread trading in Amaya Inc. stock ahead of its $4.9-billion deal for PokerStars.

According to people familiar with the investigation, the Autorité des marchés financiers (AMF) is examining the trading activities of the Manulife brokers and their family members at the branch in Dorval, which is west of Montreal.

The identities of the Manulife employees are not known, but sources described the brokers as a closely knit group that frequently socialize and share family ties.

Story continues below advertisement

Manulife lists 40 brokers, mutual fund sales staff and managers in the Dorval office, which caters to individual investors. The office is located on the busy Trans-Canada Highway, the same road on which Amaya's head office is located a few kilometres to the west.

Representatives for Manulife and the AMF declined to comment.

Tim Foran, an Amaya spokesman, said neither the company nor its executives had ties to brokers at Manulife Securities.

"Amaya is also not aware of any connection between retail brokers at Manulife Securities and any other employee at the company," he said.

Manulife Securities is the brokerage arm of Canada's insurance giant Manulife Financial Corp., which, according to the latest regulatory filings, ranks as Amaya's 17th-largest shareholder with about 300,000 of the gambling company's shares held in multiple portfolios.

The AMF is the primary regulator in a trading investigation that has attracted the attention of U.S. and Canadian regulators.

That interest resulted from the unusually active trading in Amaya's stock ahead of its announcement last June that it was buying the world's largest online gambling company.

Story continues below advertisement

Amaya's stock price and trading volumes on the Toronto Stock Exchange and the U.S. over-the-counter market soared in a 10-week period before the deal was announced in June. The unusual activity triggered a review by Wall Street's self-regulator, the Financial Industry Regulatory Authority (FINRA).

Amaya and its financial, legal and banking advisers have been asked by FINRA to answer questions about relationships or contact with about 300 investors under review. The investors, according to sources familiar with the list, purchased large amounts of Amaya stock or derivatives ahead of the takeover news.

It is believed to be the largest group of investors ever singled out by regulators for inquiries.

Regulators often review large lucky trades ahead of market-moving news, but these lists seldom number more than a few dozen. Those familiar with FINRA's list said it includes a broad cross-section of Canadian and U.S. brokers, fund managers, business executives and wealthy individuals.

The list of Amaya investors does not imply any wrongdoing or that the individuals named are the subject of an investigation.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies